BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35025076)

  • 21. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
    Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
    Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
    [No Abstract]   [Full Text] [Related]  

  • 23. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
    Wang M; Slatter S; Sussell J; Lin CW; Ogale S; Datta D; Butte AJ; Bazhenova L; Rudrapatna VA
    Target Oncol; 2023 Jul; 18(4):571-583. PubMed ID: 37341856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
    J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T; Shiraishi H; Fujiwara Y
    Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
    Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
    Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
    Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
    Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
    Front Oncol; 2021; 11():754768. PubMed ID: 34820326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
    PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
    Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
    J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
    Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
    JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
    Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.
    Zhao D; Chen J; Chu M; Long X; Wang J
    Drug Des Devel Ther; 2020; 14():1663-1681. PubMed ID: 32431491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J; Gong W
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
    Schmid S; Cheng S; Chotai S; Garcia M; Zhan L; Hueniken K; Balaratnam K; Khan K; Patel D; Grant B; Raptis R; Brown MC; Xu W; Moriarty P; Shepherd FA; Sacher AG; Leighl NB; Bradbury PA; Liu G
    Clin Lung Cancer; 2023 Jan; 24(1):40-50. PubMed ID: 36270866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
    Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Ali A; Abdel-Malek RR
    Crit Rev Oncol Hematol; 2019 Feb; 134():56-64. PubMed ID: 30771874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
    Dziadziuszko R; Peters S; Ruf T; Cardona A; Guerini E; Kurtsikidze N; Smoljanovic V; Planchard D
    ESMO Open; 2022 Dec; 7(6):100612. PubMed ID: 36375271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.